A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Trial Profile

A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Selinexor (Primary) ; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms BOSTON
  • Sponsors Karyopharm Therapeutics
  • Most Recent Events

    • 08 Aug 2017 According to a Karyopharm Therapeutics media release, the company is projecting to complete enrollment in 2018 with top-line data anticipated in 2019.
    • 07 Jun 2017 According to a Karyopharm Therapeutics media release, study is supported by robust clinical data from the STOMP study (CTP700253337).
    • 07 Jun 2017 According to a Karyopharm Therapeutics media release, data from this study will be used to support an NDA filing for selinexor for the treatment of relapsed or refractory myeloma.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top